NCT04650126View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 12, 2021

Primary Completion Date

March 24, 2022

Study Completion Date

March 24, 2022

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

ATM001

monovalent anti-TNF-receptor 1 antibody format

BIOLOGICAL

ATM001 Placebo

ATM001 Placebo

Trial Locations (1)

4006

Q-Pharm, Herston

Sponsors

Lead Sponsor

Baliopharm Pty Ltd
All Listed Sponsors
lead

Baliopharm Pty Ltd

INDUSTRY